You can’t buy a Coke, Frappuccino or Big Mac in Russia anymore, but cancer patients may still be able to get Merck’s megablockbuster Keytruda. While …

As Ukraine holds the line against the Russian invasion, pharma majors are making a renewed push to adjust operations in the region and supply the …

Neurologists in the U.S. are agreeing with a new draft decision from the Centers for Medicare & Medicaid Services (CMS) that restricts reimbursement of Biogen’s …

Now poised for a speedy trip through the FDA’s regulatory review, Roche’s oral challenger in spinal muscular atrophy (SMA) could soon pick up a nod …

The guessing is over. Roche has detailed new Polivy data that could change nearly two decades of treatment standards in newly diagnosed lymphoma—while opening up …

While many people are suffering from Zoom fatigue and looking forward to in-person meetups, that isn’t really the case when it comes to HCPs and …

Bristol Myers Squibb has expanded Opdivo’s first-in-class win in pre-surgery non-small cell lung cancer, teeing up a potential FDA filing. Opdivo added to chemotherapy before …

Roche’s Tecentriq has ushered in a new era, offering the first immunotherapy option for non-small cell lung cancer (NSCLC) patients right after tumour surgery. But …

While much of the attention on Biogen lately has centred on its launch of controversial Alzheimer’s disease drug Aduhelm, the company is also feeling the …

Roche Pharmaceuticals CEO Bill Anderson recently pegged lymphoma drug Polivy’s potential expansion into newly diagnosed patients as a multibillion-dollar opportunity. Now, at least one analyst …